Navigation Links
Rigel Announces Pricing of Public Offering of Common Stock
Date:1/31/2008

SOUTH SAN FRANCISCO, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its public offering of 5,000,000 shares of common stock at a price of $27.00 per share. All of the shares are being offered by Rigel. The underwriters have an option to purchase up to an additional 750,000 shares to cover over-allotments, if any. The offering is expected to close on February 6, 2008, subject to the satisfaction of customary closing conditions.

Credit Suisse Securities (USA) LLC is acting as the sole book-runner for the offering, with Thomas Weisel Partners LLC, Jefferies & Company, Inc. and Oppenheimer & Co. Inc. acting as co-managers.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities. A prospectus supplement relating to these securities will be filed with the Securities and Exchange Commission. This offering of shares of common stock may be made only by means of the prospectus supplement and accompanying prospectus.

Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from Credit Suisse Securities (USA) LLC, Prospectus Department, One Madison Avenue, New York, New York 10010-3629 (Telephone number 1-800-221-1037).

About Rigel (http://www.rigel.com)

We are a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases. Our goal is to file one new investigative new drug application in a significant indication each year. We have achieved this goal each year beginning in 2002.
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/21/2014)... have discovered how to produce ultra-thin "diamond nanothreads" that ... that of today,s strongest nanotubes and polymers. A paper ... John V. Badding, a professor of chemistry at Penn ... 2014 issue of the journal Nature Materials . ... is intriguing because the threads we formed have a ...
(Date:9/20/2014)... Austin, Texas (PRWEB) September 20, 2014 ... of integrated urological and interventional radiology products and ... Endocare, Inc. subsidiary with Clinicon Corporation ... addition expands HealthTronics’ portfolio of minimally invasive, mobile, ... their patients. , Under the agreement, HealthTronics will ...
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Want to link genes to complex traits? Start with more diversity 2
... 2011 Arecor, the leading company ... and vaccines, is pleased to announce the appointment ... Howell will be responsible for the operations of ... Arecor,s upward growth curve ensuring the company continues ...
... Nov. 10, 2011 Avaxia Biologics, Inc. , ... act locally within the gastrointestinal tract, announced today that ... of a Series A angel-led financing. Cherrystone Angels of ... Boston Harbor Angels and other undisclosed individuals. Mr. Robert ...
... Discovery Laboratories, Inc. (Nasdaq: DSCO ), ... respiratory critical care, today reports financial results for the third ... of the SURFAXIN® and AFECTAIR™ programs.  The Company will host ... call details are below. Selected third quarter highlights ...
Cached Biology Technology:Arecor Appoints Dr. Sarah Howell as Chief Operating Officer 2Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 3Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 4Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 5Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 6Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 7Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 8Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 9
(Date:9/22/2014)... in the country selected by the National Institutes ... Award a $2 million grant designed to ... sciences graduate trainees to career opportunities that go ... taken. , The award funds development of the ... program. It includes courses, seminars, shadowing, mentoring and ...
(Date:9/22/2014)... Evacuations of 2,819 people have occurred in the wake ... near the Eldorado National Forest. The King Fire ... of the American River Canyon, Silver Creek Canyon, and ... Pines. The fire has crossed into Placer County and ... Eldorado National Forest. The anticipated spread is expected to ...
(Date:9/21/2014)... General Assembly events focussed on ways to save and ... Challenges Canada, funded by the Government of Canada, today ... to address this challenge. , The novel approaches include: ... working in garment factories to express, pasteurize and store ... due to child illnesses, and lowering baby formula expense ...
Breaking Biology News(10 mins):Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 2Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 4Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 5Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 6Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 7Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 8Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 9Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 10Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 11Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 12Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 13Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 14Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 15
... 2010 Cellular imaging offers a wealth of data ... technique to study biological systems is a daunting challenge. ... Research ( www.genome.org ), researchers have developed a ... identify genetic interactions within biological networks, offering a glimpse ...
... in third-hand smoke, the residue from tobacco smoke that ... has been extinguished, reacts with the common indoor air ... potential health hazard was revealed in a multi-institutional study ... (Berkeley Lab). "The burning of tobacco releases nicotine ...
... Advanced maternal age is linked to a significantly elevated risk ... age, according to an exhaustive study of all births in ... Advanced paternal age is associated with elevated autism risk only ... 30, the study found. Published online today in the ...
Cached Biology News:Method of the future uses single-cell imaging to identify gene interactions 2Study reveals new details on the dangers of third-hand smoke 2Study reveals new details on the dangers of third-hand smoke 3Study reveals new details on the dangers of third-hand smoke 4UC Davis study confirms link between advanced maternal age and autism 2UC Davis study confirms link between advanced maternal age and autism 3UC Davis study confirms link between advanced maternal age and autism 4
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: